{"title":"Predictive Value of <sup>18</sup>F-FDG PET/CT in LA-HNSCC Patients Undergoing Neoadjuvant Chemoimmunotherapy: A Prospective Study.","authors":"Rong Huang, Xiaoxu Lu, Xueming Sun, Hui Wu","doi":"10.1111/odi.15276","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The study evaluates the efficacy of <sup>18</sup>F-2-fluoro-2-deoxy-d-glucose FDG PET/CT in predicting outcomes in patients with advanced head and neck squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy.</p><p><strong>Methods: </strong>In this prospective study, we compared the parameters of 63 patients with LA-HNSCC who underwent <sup>18</sup>F-FDG PET/CT before neoadjuvant chemoimmunotherapy, divided into responders (47) and non-responders (16), after three cycles of neoadjuvant chemoimmunotherapy. The ratio of the maximum standardized uptake value (SUVmax) of the primary tumor to the SUVmean of the normal tissue (muscle and blood) was recorded as the target background ratio (TBR muscle and TBR blood).</p><p><strong>Results: </strong>The SUVmean and TBRblood of the primary tumor were significantly lower in the responding group than in the non-responding group. Receiver operating characteristic (ROC) curve analysis identified SUVmean (area under the curve (AUC) = 0.931, p = 0.001) and TBRblood (AUC = 0.894, p = 0.001) as significant predictors of neoadjuvant chemoimmunotherapy efficacy. The study found that SUVmean, TBRblood, age, and Eastern Cooperative Oncology Group (ECOG) scores significantly correlated with short-term efficacy, while SUVmean was an independent predictor.</p><p><strong>Conclusion: </strong>In <sup>18</sup>F-FDG PET/CT scans, higher baseline SUVmean and TBRblood were associated with a poor short-term response to neoadjuvant chemoradiotherapy in patients with LA-HNSCC.</p>","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15276","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The study evaluates the efficacy of 18F-2-fluoro-2-deoxy-d-glucose FDG PET/CT in predicting outcomes in patients with advanced head and neck squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy.
Methods: In this prospective study, we compared the parameters of 63 patients with LA-HNSCC who underwent 18F-FDG PET/CT before neoadjuvant chemoimmunotherapy, divided into responders (47) and non-responders (16), after three cycles of neoadjuvant chemoimmunotherapy. The ratio of the maximum standardized uptake value (SUVmax) of the primary tumor to the SUVmean of the normal tissue (muscle and blood) was recorded as the target background ratio (TBR muscle and TBR blood).
Results: The SUVmean and TBRblood of the primary tumor were significantly lower in the responding group than in the non-responding group. Receiver operating characteristic (ROC) curve analysis identified SUVmean (area under the curve (AUC) = 0.931, p = 0.001) and TBRblood (AUC = 0.894, p = 0.001) as significant predictors of neoadjuvant chemoimmunotherapy efficacy. The study found that SUVmean, TBRblood, age, and Eastern Cooperative Oncology Group (ECOG) scores significantly correlated with short-term efficacy, while SUVmean was an independent predictor.
Conclusion: In 18F-FDG PET/CT scans, higher baseline SUVmean and TBRblood were associated with a poor short-term response to neoadjuvant chemoradiotherapy in patients with LA-HNSCC.
期刊介绍:
Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.